Lexaria Bioscience Corp. (NASDAQ: LEXX) has remained committed to improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream. “Moreover, as a global innovator in drug delivery platforms, the company has not shied away from advancing its research to cut across various health conditions, including but not limited to hypertension, epilepsy, diabetes, and dementia, among others. These efforts have yielded 27 granted patents around the world since 2014, with approximately 50 additional patents pending. It also has national filings in over 40 jurisdictions with the highest commercial potential, reflecting the company’s commitment to creating shareholder value and pushing its technology further into the market,” a recent article reads. “Through its four subsidiary companies, Lexaria has explored various sectors such as cannabidiol for hypertension, oral nicotine for reduced risk, and antiviral drugs for COVID-19 and other infectious diseases. The progress so far has also allowed Lexaria to sub-license its DehydraTECH(TM) worldwide for delivering fat-soluble active molecules and drugs, thereby increasing the number of people who benefit from this technology and the number of lives impacted by it… As it pushes for the approval of additional patents and the licensing of its technology, the company looks to grow its market share significantly while redefining drug delivery platforms.”
To view the full article, visit https://ibn.fm/CpDjD
About Lexaria Bioscience Corp.
Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 27 patents granted and roughly 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
